Rigel Pharmaceuticals Inc (RIGL)
0.9504
-0.03
(-3.27%)
USD |
NASDAQ |
May 17, 16:00
1.02
+0.07
(+7.32%)
After-Hours: 20:00
Rigel Pharmaceuticals Accounts Payable (Quarterly): 9.276M for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 9.276M |
December 31, 2023 | 7.142M |
September 30, 2023 | 7.999M |
June 30, 2023 | 5.24M |
March 31, 2023 | 6.295M |
December 31, 2022 | 22.51M |
September 30, 2022 | 2.721M |
June 30, 2022 | 2.155M |
March 31, 2022 | 4.614M |
December 31, 2021 | 3.795M |
September 30, 2021 | 3.144M |
June 30, 2021 | 1.689M |
March 31, 2021 | 5.095M |
December 31, 2020 | 3.707M |
September 30, 2020 | 2.283M |
June 30, 2020 | 3.414M |
March 31, 2020 | 2.207M |
December 31, 2019 | 4.152M |
September 30, 2019 | 2.661M |
June 30, 2019 | 3.777M |
March 31, 2019 | 1.179M |
December 31, 2018 | 6.391M |
September 30, 2018 | 2.641M |
June 30, 2018 | 3.342M |
March 31, 2018 | 2.623M |
Date | Value |
---|---|
December 31, 2017 | 2.636M |
September 30, 2017 | 2.193M |
June 30, 2017 | 2.066M |
March 31, 2017 | 1.178M |
December 31, 2016 | 5.563M |
September 30, 2016 | 1.518M |
June 30, 2016 | 1.506M |
March 31, 2016 | 2.424M |
December 31, 2015 | 2.763M |
September 30, 2015 | 0.689M |
June 30, 2015 | 1.096M |
March 31, 2015 | 1.136M |
December 31, 2014 | 1.613M |
September 30, 2014 | 1.018M |
June 30, 2014 | 1.896M |
March 31, 2014 | 1.157M |
December 31, 2013 | 3.903M |
September 30, 2013 | 1.025M |
June 30, 2013 | 2.121M |
March 31, 2013 | 2.138M |
December 31, 2012 | 1.697M |
September 30, 2012 | 1.388M |
June 30, 2012 | 1.912M |
March 31, 2012 | 1.922M |
December 31, 2011 | 1.556M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
1.689M
Minimum
Jun 2021
22.51M
Maximum
Dec 2022
5.194M
Average
3.786M
Median
Accounts Payable (Quarterly) Benchmarks
Nektar Therapeutics | 8.757M |
Avid Bioservices Inc | 19.51M |
Stereotaxis Inc | 3.307M |
Cara Therapeutics Inc | 4.978M |
Ardelyx Inc | 17.28M |